Kidney- and site-selective delivery of 5-fluorouracil utilizing the absorption on the kidney surface in rats

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 7, 2002, Pages 928-930

  Kawakami, Shigeru ^a   Horimoto, Tomomi ^a   Nishida, Koyo ^a   Hirayama, Ryu ^a   Mukai, Takahiro ^a   Nakashima, Mikiro ^a   Sasaki, Hitoshi ^a   Sakaeda, Toshiyuki ^b   Nakamura, Junzo ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Anticancer drug; Drug delivery system; Kidney; Rat; Targeting

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; KIDNEY; NONHUMAN; RAT; SURFACE PROPERTY; ANIMAL; COMPARATIVE STUDY; MALE; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION; WISTAR RAT;

ABSORPTION; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG DELIVERY SYSTEMS; FLUOROURACIL; KIDNEY; MALE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0036634097     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.928     Document Type: Article

References (16)

1. Thompson I. M., Peek M., J. Urol., 140, 487-490 (1988).
2. Motzer R. J., Russo P., J. Urol., 163, 408-417 (2000).
3. Noda S., Konno S., Tanaka J., Yamada M., Yoshitake N., Anticancer Res., 10, 709-716 (1990).
4. Kobayashi M., Maeda H., Imai K., Konno T., Sugihara S., Yamanaka H., Urology, 37, 288-294 (1991).
5. Kato T., Nemoto R., Mori H., Takahashi M., Tamakawa Y., J. Urol., 125, 19-24 (1981).
6. Kato T., Sato K., Sasaki R., Kakinuma H., Moriyama M., Cancer Chemother. Pharmacol., 37, 289-296 (1996).
7. Kerr D. J., Willmott N., McKillop J. H., Cummings J., Lewi H. J., McArdle C. S., Cancer, 62, 878-883 (1988).
8. McArdle C. S., Lewi H., Hansell D., Kerr D. J., McKillop J., Willmott N., Br. J. Surg., 75, 132-134 (1988).
9. Pyrhönen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., Tammela T., Juusela H., Rintala E., Hietanen P., Kellokumpu-Lehtinen P.-L., J. Clin. Oncol., 17, 2859-2867 (1999).
10. Watanabe J., Hayashi Y., Iwamoto K., Ozeki S., Chem. Pharm. Bull., 33, 1187-1194 (1985).
11. Sawai Y., Yamaoka K., Ito T., Nakagawa T., Biol. Pharm. Bull., 20, 1313-1316 (1997).
12. Yagoda A., Abi-Rached B., Petrylak D., Semin. Oncol., 22, 42-60 (1995).
13. Phillips T. A., Howell A., Grieve R. J., Welling P. G., J. Pharm. Sci., 69, 1428-1431 (1980).
14. Diasio R. B., Harris B. E., Clin. Pharmacokinet., 16, 215-237 (1989).
15. Fata F., Ron I. G., Kemeny N., O'Reilly E., Klimstra D., Kelsen D. P., Cancer, 86, 1129-1134 (1999).
16. Nishida K., Sato N., Sasaki H., Nakamura J., J. Pharm. Pharmacol., 46, 867-870 (1994).